Related references
Note: Only part of the references are listed.Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline
Megan E. Daly et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population
Ali Raza Khaki et al.
JCO ONCOLOGY PRACTICE (2021)
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre-Finn et al.
LUNG CANCER (2021)
Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
Abdul Rahman Jazieh et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
N. Girard et al.
ANNALS OF ONCOLOGY (2021)
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
J. Remon et al.
ANNALS OF ONCOLOGY (2021)
Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer
Anna Hung et al.
BMC CANCER (2021)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
K. Park et al.
ANNALS OF ONCOLOGY (2020)
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Hiro Sato et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters
Kuniaki Katsui et al.
CANCER MEDICINE (2020)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
David M. Waterhouse et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada
S. J. Seung et al.
CURRENT ONCOLOGY (2020)
Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec
J. Agulnik et al.
CURRENT ONCOLOGY (2020)
1459PDEfficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
J F Vansteenkiste et al.
ANNALS OF ONCOLOGY (2019)
339TiPPACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Y-L Wu et al.
ANNALS OF ONCOLOGY (2019)
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
Rina Hui et al.
LANCET ONCOLOGY (2019)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
J. Vansteenkiste et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Curative Intent Treatment for Stage III NSCLC in England
S. Harden et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
T. Kordbacheh et al.
ANNALS OF ONCOLOGY (2018)
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
Stephen G. Chun et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium
I. Walraven et al.
CLINICAL ONCOLOGY (2017)
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Simon J. Dovedi et al.
CLINICAL CANCER RESEARCH (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. E. Postmus et al.
ANNALS OF ONCOLOGY (2017)
The Eighth Edition Lung Cancer Stage Classification
Frank C. Detterbeck et al.
CHEST (2017)
Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice
Elisabeth J. M. Driessen et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Management of Patients With Lung Cancer and Poor Performance Status
Ajeet Gajra et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Prognostic Significance of Tumor Size in Patients with Stage III Non-Small-Cell Lung Cancer A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003
Daniel Morgensztern et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Walter J. Curran et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It's no longer the question: a systematic review
Hui-Ying Liang et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
Anne Auperin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study
D. De Ruysscher et al.
ANNALS OF ONCOLOGY (2009)
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
A. Brunelli et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Share Paper
